Update

ACT-AD Expresses Support for Food and Drug Administration Safety and Innovation Act

ACT-AD expresses support for Food and Drug Administration Safety and Innovation Act (FDASIA) because of provisions aimed at accelerating drug development through greater focus on regulatory science; supporting the development of innovative clinical trial designs; re-evaluating how the FDA assesses benefits and risks of therapies and communicates benefit-risk information; and ensuring that Risk Evaluation and Mitigation Strategies (REMS) do not serve as a barrier to patients in need of treatments.
View Letter

File Attachments
Categories:
Uncategorized